comparemela.com

Page 4 - Hans Vassg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation

Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation Oslo, 5 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines

Hans vassg

Correction: Ultimovacs ASA: Annual Report 2021

Oslo, 25 March 2021: Ultimovacs ASA ("Ultimovacs", ticker ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces that the Board of Directors of Ultimovacs ASA has approved

Hans vassgAnnual reportCarlos de sousaChief executiveEuropean single electronic formatNorwegian securities trading

Ultimovacs ASA: Fourth quarter 2021 result presentation

Oslo, 17 February 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation

Joachim midttunMary ann changHans vassgOrphan drugFast trackAlthough ultimovacsAnn changAbuse regulationNorwegian securities tradingFinance manager

Investegate |Ultimovacs ASA Announcements | Ultimovacs ASA: Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

Investegate announcements from Ultimovacs ASA, Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

Mary ann changHans vassgDrug administrationOffice of orphan products developmentUltimovacs granted orphan drug designationMetastatic melanomaOrphan products developmentFast trackCarlos de sousaAnn changAbuse regulationNorwegian securities tradingInvestegate announcementsInvestegate company announcementsUltimovacs asaLobenewswire and globenewswire

Ultimovacs ASA: Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

Designation covers UV1 in Metastatic Melanoma as sole agent or part of combinationSeven-year market exclusivity after regulatory approval, if received Oslo, 2 December 2021: Ultimovacs ASA

Joachim midttunMary ann changHans vassgDrug administrationOffice of orphan products developmentMetastatic melanomaOrphan products developmentFast trackCarlos de sousaAnn changAbuse regulationNorwegian securities tradingFinance manager

vimarsana © 2020. All Rights Reserved.